These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 19588525)

  • 1. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
    Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M; Qian J; Andreou C; Pommerville P; Chin J; Casey R; Steinhoff G; Fleshner N; Bostwick D; Thomas L; Rittmaster R
    Prostate; 2006 Nov; 66(15):1674-85. PubMed ID: 16927304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
    J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
    J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
    Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular PCA3 diagnostics on prostatic fluid.
    van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
    Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
    Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
    Bepple JL; Barone BB; Eure G
    Urology; 2009 Nov; 74(5):1101-4. PubMed ID: 19800668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.